Trop-2-Directed ADC Sacituzumab Govitecan Earns FDA Approval in First-Line Metastatic Triple-Negative Breast Cancer

A Trop-2-directed antibody-drug conjugate (ADC) built on a proprietary hydrolyzable linker has secured its most expansive regulatory authorization to date, with the FDA’s approval of sacituzumab govitecan-hziy (Trodelvy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).¹

The decision, supported by statistically significant Phase 3 data, extends the molecule's approved footprint into the initial treatment setting and positions the conjugate's linker-payload architecture as a validated design strategy within an increasingly competitive ADC development landscape.

The approval covers two distinct populations stratified by immunotherapy eligibility: patients ineligible for checkpoint inhibitor-based therapy may receive the drug as a single agent, while those with PD-L1-positive tumors (combined positive score ≥10) may receive it in combination with pembrolizumab (Keytruda) or its subcutaneous co-formulation, pembrolizumab and berahyaluronidase alfa-mph.¹ The dual-pathway structure of the label reflects a regulatory approach that accommodates biomarker-stratified development programs within a single approval action.

"For people living with mTNBC, the first treatment choice can be pivotal, as many patients may not have the opportunity to receive subsequent therapies," said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and a principal investigator of the supporting trials, in a press release. "This approval is heartening news for patients and the clinical community, and I believe offers a practice-changing first-line treatment option for all patients across PD-L1 status."¹

What Does the Sacituzumab Govitecan ADC Platform Design Reveal About Linker-Payload Engineering?

Sacituzumab govitecan targets Trop-2, a cell-surface transmembrane glycoprotein with high expression in more than 90% of breast cancers and across a range of solid tumor types. The molecule's payload, SN-38, is the active metabolite of irinotecan and functions as a topoisomerase I inhibitor.

What distinguishes the conjugate architecturally is its use of a hydrolyzable carbonate linker rather than a protease-cleavable design: the linker releases SN-38 in a pH-sensitive manner, enabling payload delivery not only to antigen-expressing tumor cells but also to adjacent cells in the tumor microenvironment through a bystander effect.¹

This design carries a drug-to-antibody ratio of approximately 7.6, higher than many approved conjugates, which contributes to both its efficacy profile and its toxicity burden. The molecular approach has now demonstrated clinical activity across four positive Phase 3 trials in HER2-negative metastatic breast cancer, providing an increasingly robust evidence base for the Trop-2/SN-38/hydrolyzable linker combination as a development platform with reproducible results across lines of therapy and tumor subtypes.

What Phase 3 Evidence Supported the FDA's Regulatory Decision?

The approval rests on data from two randomized Phase 3 studies. ASCENT-03 (NCT05382299) enrolled 558 patients with previously untreated locally advanced or mTNBC who were ineligible for checkpoint inhibitor therapy and randomized them 1:1 to sacituzumab govitecan or physician's choice of chemotherapy.²

The primary endpoint of progression-free survival (PFS) by blinded independent central review was 9.7 months in the sacituzumab govitecan cohort versus 6.9 months, a 38% reduction in the risk of disease progression or death (hazard ratio 0.62; 95% confidence interval, 0.50–0.77; P<0.0001).² Median duration of response was 12.2 months with the conjugate versus 7.2 months with chemotherapy.

ASCENT-04/KEYNOTE-D19 (NCT05382286) enrolled 443 patients with PD-L1-positive, previously untreated locally advanced or mTNBC and randomized them to sacituzumab govitecan plus pembrolizumab or chemotherapy plus pembrolizumab.³ The combination arm achieved a median PFS of 11.2 months versus 7.8 months, a 35% reduction in the risk of progression or death (hazard ratio 0.65; 95% confidence interval, 0.51–0.84; P<0.001).³

Duration of response in the combination arm extended to 16.5 months compared with 9.2 months in the chemotherapy-based arm. Overall survival (OS) data remained immature at the time of primary analysis in both studies.

The trial designs are notable for their use of an active chemotherapy comparator rather than placebo, and for independently validating the molecule's activity in two biologically distinct first-line mTNBC subpopulations.

How Does the mTNBC Setting Shape Drug Development and Regulatory Strategy?

Triple-negative breast cancer, defined by the absence of estrogen and progesterone receptor expression and limited HER2 expression, represents roughly 10% to 15% of all breast cancers and is associated with a substantially worse prognosis than hormone receptor-positive subtypes.⁴ The disease disproportionately affects younger, premenopausal women and Black and Hispanic patients, and carries a five-year survival rate of approximately 12% in the metastatic setting, compared with 28% for other metastatic breast cancer subtypes.

From a development standpoint, mTNBC presents a specific challenge: more than half of patients do not receive a second line of therapy, which means efficacy signals achieved in first-line trials cannot be assumed to translate from later-line studies. The ASCENT program's sequential development—establishing proof of concept in second-line disease with the pivotal ASCENT trial, then advancing into the first-line setting—reflects a staged regulatory strategy that is increasingly common for oncology biologics and conjugates.

"TNBC disproportionately affects younger women—many in the prime of their lives—and often leads to poorer outcomes," said Ricki Fairley, co-founder and CEO of TOUCH, The Black Breast Cancer Alliance, in a press release. "Because so many patients may never receive subsequent lines of therapy, the ability to start with a promising option like Trodelvy with or without Keytruda is critical."

What Are the Safety and Pharmacogenomic Considerations for the SN-38 Payload?

Sacituzumab govitecan carries a boxed warning for severe neutropenia and diarrhea, both of which are attributable to the SN-38 payload and are consistent with the known toxicity profile of irinotecan-based therapies. In ASCENT-03, serious adverse reactions occurred in 26% of patients and fatal adverse reactions in 2.5%.

In ASCENT-04, serious adverse reactions were reported in 38% of patients and fatal adverse reactions in 3.2%, reflecting the additive immunosuppressive effects of the pembrolizumab combination. Febrile neutropenia, diarrhea, and pneumonia were the most frequently cited serious events across both studies.

A pharmacogenomic consideration relevant to development and labeling is the UGT1A1*28 allele. Patients homozygous for this allele have reduced UGT1A1 enzyme activity, impairing glucuronidation and detoxification of SN-38 and increasing systemic exposure to the active payload. Grade 3–4 neutropenia rates were notably higher in this genotype subgroup, and the prescribing information calls for close monitoring and potential dose modification.

This pharmacogenomic dependency is a factor that development teams working with irinotecan-based payloads must account for in study design, patient selection, and labeling strategy.

What Are the Remaining Development and Regulatory Questions?

OS data from both ASCENT-03 and ASCENT-04 remain immature, and the magnitude and durability of the survival benefit—a key consideration for payer negotiations and label evolution—will not be known until follow-up matures. The absence of a direct monotherapy-versus-combination comparison in PD-L1-positive patients also leaves unanswered questions about optimal treatment sequencing and biomarker-guided selection.

Global regulatory submissions based on the two trials are underway. The molecule is also being evaluated in ongoing Phase 3 programs across additional Trop-2-expressing tumor types, including earlier-line hormone receptor-positive and HER2-negative breast cancer, lung, and gynecologic cancers, extending the platform's development scope well beyond its current approvals across more than 60 countries.

Sources

1. Gilead Sciences, Inc. U.S. FDA approves Trodelvy for first-line treatment of metastatic triple-negative breast cancer. News release. June 24, 2026. https://www.gilead.com/news/news-details/2026/u-s--fda-approves-trodelvy-for-first-line-treatment-of-metastatic-triple-negative-breast-cancer

2. Cortés J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025. doi:10.1056/NEJMoa2511734

3. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med. 2026;394(4):354-366. doi:10.1056/NEJMoa2508959

4. U.S. Food and Drug Administration. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. June 24, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line